Cost of Revenue Comparison: Pfizer Inc. vs Geron Corporation

Cost of Revenue: A Tale of Two Companies

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. Pfizer Inc., a global giant, and Geron Corporation, a smaller biotech firm, present a fascinating contrast in their cost of revenue from 2014 to 2023. Pfizer's cost of revenue consistently dwarfs Geron's, with Pfizer's 2023 figure reaching nearly $30 billion, a staggering 2,400% higher than Geron's $123 million. This disparity highlights the scale at which Pfizer operates compared to Geron. Notably, Pfizer's cost of revenue surged by over 250% from 2020 to 2022, reflecting its strategic investments and market expansion. Meanwhile, Geron's costs remained relatively stable, with a notable spike in 2023, indicating potential growth or increased operational expenses. This comparison underscores the diverse financial landscapes within the pharmaceutical sector, offering insights into how companies of different sizes manage their resources.